reports
AB SA: 2 directors
Two Directors at AB SA sold 3,065,252 shares at 87.000PLN. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
- ING Helpdesk
- Robert Jan Vos
- Usama Tariq
- Robert Jan Vos
- Usama Tariq
- Cor Kluis
- ING Helpdesk
Benelux Morning Notes
Ageas: Highlights ING Benelux Conference London. Alfen: Highlights from ING Benelux Conference London. Arcadis: Highlights ING Benelux Conference London. ASR: Highlights ING Benelux Conference London. BAM: Highlights ING Benelux Conference London. Basic-Fit: Highlights ING Benelux Conference London. CTP: Highlights from ING Benelux Conference London. DEME Group: Highlights ING Benelux Conference London. Fugro: Highlights ING Benelux Conference London. Heijmans: Highlights ING Bene...
SBMO SBM OFFSHORE NV
AGS AGEAS SA/NV
RAND RANDSTAD NV
PNL POSTNL NV
BAMNB KONINKLIJKE BAM GROEP NV
LOTB LOTUS BAKERIES NV
HEIJM HEIJMANS N.V. CERT
ARCAD
ARCADIS NV
ASRNL ROYAL VOPAK NV
TWEKA ASR NEDERLAND NV
ALFEN TKH GROUP N.V. CERT
FUR ALFEN NV
CTPNV FUGRO NV
DEME CTP NV
DEME GROUP NV
- Andreas Riemann
- Oliver Metzger
CON CONTINENTAL AKTIENGESELLSCHAFT
NDX1 NORDEX SE
FRA FRAPORT AG
TEMN TEMENOS AG
TKA THYSSENKRUPP AG
WCH WACKER CHEMIE AG
G1A GEA GROUP AG
MTX MTU AERO ENGINES AG
GBF BILFINGER SE
STF STEF
LXS LANXESS AG
GXI GERRESHEIMER AG
BLC BASTIDE LE CONFORT MEDICAL SA
VNA VONOVIA SE
EOAN E.ON SE
BOSS HUGO BOSS AG
HEN3 HENKEL AG & CO. KGAA PREF
DEZ DEUTZ AG
INH INDUS HOLDING AG
KRN KRONES AG
WIE WIENERBERGER AG
GREEN GREENYARD NV
KGX KION GROUP AG
TWEKA TKH GROUP N.V. CERT
VLTSA VOLTALIA
HBH HORNBACH HOLDING AG & CO. KGAA
JUN3 JUNGHEINRICH AG PREF
JST JOST WERKE AG
DMP DERMAPHARM HOLDING SE
VOS VOSSLOH AG
JEN JENOPTIK AG
EAT AMREST HOLDINGS SE
KBX KNORR-BREMSE AG
SFQ SAF-HOLLAND SE
STM STABILUS SE
TUI TUI AG
- Andreas Riemann
- Oliver Metzger
CON CONTINENTAL AKTIENGESELLSCHAFT
NDX1 NORDEX SE
FRA FRAPORT AG
TEMN TEMENOS AG
TKA THYSSENKRUPP AG
WCH WACKER CHEMIE AG
G1A GEA GROUP AG
MTX MTU AERO ENGINES AG
GBF BILFINGER SE
STF STEF
LXS LANXESS AG
GXI GERRESHEIMER AG
BLC BASTIDE LE CONFORT MEDICAL SA
VNA VONOVIA SE
EOAN E.ON SE
BOSS HUGO BOSS AG
HEN3 HENKEL AG & CO. KGAA PREF
DEZ DEUTZ AG
INH INDUS HOLDING AG
KRN KRONES AG
WIE WIENERBERGER AG
GREEN GREENYARD NV
KGX KION GROUP AG
TWEKA TKH GROUP N.V. CERT
VLTSA VOLTALIA
HBH HORNBACH HOLDING AG & CO. KGAA
JUN3 JUNGHEINRICH AG PREF
JST JOST WERKE AG
DMP DERMAPHARM HOLDING SE
VOS VOSSLOH AG
JEN JENOPTIK AG
EAT AMREST HOLDINGS SE
KBX KNORR-BREMSE AG
SFQ SAF-HOLLAND SE
STM STABILUS SE
TUI TUI AG
- Robert Jan Vos
Inventiva to Participate in Upcoming September Investor Conferences
Inventiva to Participate in Upcoming September Investor Conferences Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in the following upcoming investor events: H.C. Wainwright 27th Annual Global Investment ConferenceDate: Tuesday, September 9, 2025Time of the fi...
Inventiva annonce sa participation à plusieurs conférences investisseu...
Inventiva annonce sa participation à plusieurs conférences investisseurs en septembre Daix (France), New York City (New York, Etats-Unis), le 4 septembre 2025 – (Euronext Paris et Nasdaq : ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que son équipe de direction participera aux conférences investisseurs suivantes :H.C. Wainwright 27th Annual Global Investment Conference Date : Mardi 9 septembre 2025Heur...
- ING Helpdesk
- Wim Hoste
Recticel Conference call feedback & model update
Recticel has posted solid double digit top line growth in 1H25 with a flattish adj EBITDA margin. The € 27.7m adj EBITDA figure was c. 8% below our forecast and 7% below consensus. The fresh FY25 adjusted EBITDA guidance calls for c. 10% growth which was below our and consensus forecasts (of c. +24%). Positive is that building permit levels are starting to pick up in some geographies. The strategic growth projects in the US (Insulated Panels Plant) and Belgium (Recycling plant) are progressing a...
- ING Helpdesk
Benelux Morning Notes
Ackermans & van Haaren: A strong 1H25. Avantium: Nearly there. Eurocommercial Properties: Good results, positive effects of remerchandising. Recticel: Weak 1H25 calls for a 12% downgrade to consensus at Adj. EBITDA level. Sif Group: 2025 and 2026 guidance cuts. Staffing: Belgium - July Temp volume weaker at -3.5% YoY despite easier comps
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Lynn Hautekeete
- Wim Hoste
- Wim Lewi
- Wim Hoste
Recticel FIRST LOOK: 1H adj.EBITDA +10%, FY EBITDA growth guidance of ...
Recticel has posted solid double digit top line growth in 1H25 with a flattish adj EBITDA margin. The € 27.7m adj EBITDA figure was c. 8% below our forecast and 7% below consensus. The fresh FY25 adjusted EBITDA guidance calls for c. 10% growth which is below our and consensus forecasts (of c. +24%). Positive is that building permit levels are starting to pick up in some geographies. The strategic growth projects in the US (Insulated Panels Plant) and Belgium (Recycling plant) are progressing ac...
- Stefano Toffano
- Stefano Toffano
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Thibault Leneeuw
- Thomas Couvreur
- Wim Lewi
- Jacob Mekhael
Inventiva A MASH turnaround story with big upside potential
Inventiva's lanifibranor is the next in line candidate in MASH, with its phase 3 (NATiV3) trial now fully recruited, locking in a topline readout for 2H26. The program is de-risked by a robust phase 2b, showing competitive fibrosis response rates and strong HbA1c reduction— a key differentiator for the large MASH + T2D population. With oral dosing and clean safety, lanifibranor is well-positioned to capture a meaningful share of the validated MASH commercial opportunity. A € 348m structured fina...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.